Bristol-Myers Squibb

YTD

ALL

Trade Bristol-Myers Squibb 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMY

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies.

CEO

Christopher S. Boerner

CEOChristopher S. Boerner

Employees

32,500

Employees32,500

Headquarters

Princeton, New Jersey

HeadquartersPrinceton, New Jersey

Founded

1933

Founded1933

Employees

32,500

Employees32,500

BMY Key Statistics

Market cap

121.54B

Market cap121.54B

Price-Earnings ratio

16.92

Price-Earnings ratio16.92

Dividend yield

4.25%

Dividend yield4.25%

Average volume

15.95M

Average volume15.95M

High today

$59.88

High today$59.88

Low today

$58.92

Low today$58.92

Open price

$59.66

Open price$59.66

Volume

2.68M

Volume2.68M

52 Week high

$62.89

52 Week high$62.89

52 Week low

$42.52

52 Week low$42.52

Stock Snapshot

The current Bristol-Myers Squibb(BMY) stock price is $59.68, with a market capitalization of 121.54B. The stock trades at a price-to-earnings (P/E) ratio of 16.92 and offers a dividend yield of 4.3%.

During the trading session on 2026-03-30, Bristol-Myers Squibb(BMY) shares reached a daily high of $59.88 and a low of $58.92. At a current price of $59.68, the stock is +1.3% higher than the low and still -0.3% under the high.

Trading volume for Bristol-Myers Squibb(BMY) stock has reached 2.68M, versus its average volume of 15.95M.

Over the past 52 weeks, Bristol-Myers Squibb(BMY) stock has traded between a high of $62.89 and a low of $42.52.

BMY News

Simply Wall St 1d

A Look At Bristol Myers Squibb Valuation As Growth Portfolio Outperforms Recent GAAP Loss

Advertisement Why Bristol-Myers Squibb (BMY) is on investors’ radar Bristol-Myers Squibb (BMY) is drawing attention after recent share price moves, with the s...

TipRanks 3d

Bristol-Myers Squibb’s Repotrectinib DDI Study: What Investors Should Watch

Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study. The Phase 1 study “Phase 1, 2-Cohort, Open-label, Fixed-sequence, Drug-...

TipRanks 3d

Milvexian Phase 3 Wraps Up: What Bristol-Myers Squibb Investors Should Watch Next

Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study. The Phase 3 study “A Phase 3, Randomized, Double-blind, Placebo-control...

Analyst ratings

59%

of 32 ratings

Buy

37.5%

Hold

59.4%

Sell

3.1%

People also own

Based on the portfolios of people who own BMY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.